The Eli Lilly-backed liver disease drug developer floated at the top of its range to raise almost $128m, following $207m of venture funding.

Terns Pharmaceuticals, a US-based liver disease therapeutics developer that counts pharmaceutical firm Eli Lilly as its largest investor, has secured approximately $128m in its initial public offering. The offering consisted of 7.5 million shares issued on the Nasdaq Global Market priced at the top of its $15 to $17 range. The company floated on Friday…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.